Clinical characteristics of the training set
| Characteristic . | Value . | P . |
|---|---|---|
| Male sex, no. (%) | ||
| Responders | 15 (63) | 1.00 |
| Nonresponders | 7 (58) | |
| Median age at diagnosis, y (range) | ||
| Responders | 51 (28-76) | .048 |
| Nonresponders | 61 (24-71) | |
| Hemoglobin, g/dL | ||
| Responders | 13.1 (10.0-16.3) | .575 |
| Nonresponders | 12.5 (10.3-15.8) | |
| White cell count, ×103/L | ||
| Responders | 12.0 (2.5-70.8) | .373 |
| Nonresponders | 17.8 (4.7-116) | |
| Platelet count, ×103/L | ||
| Responders | 265.5 (19-935) | .098 |
| Nonresponders | 350 (99-1372) | |
| Peripheral blood basophil count, % | ||
| Responders | 4 (0-31) | .938 |
| Nonresponders | 6 (0-16) | |
| Peripheral blood eosinophil count, % | ||
| Responders | 1 (0-8) | .441 |
| Nonresponders | 2 (0-3) | |
| Peripheral blood blast count, % | ||
| Responders | 0 (0-11) | .657 |
| Nonresponders | 0 (0-5) | |
| Bone marrow blast count, % | ||
| Responders | 1 (0-13) | .234 |
| Nonresponders | 3 (0-18) | |
| Spleen size, cm below costal margin | ||
| Responders | 0 (0-11) | .806 |
| Nonresponders | 0 (0-10) | |
| Chronic phase with CE* | ||
| Responders | 6 (26) | .874 |
| Nonresponders | 3 (27) | |
| Deletion of derived chromosome 9, no. (%) | ||
| Responders | 2 (8) | .717 |
| Nonresponders | 1 (8) | |
| Prior hydroxyurea therapy | ||
| Responders | 20 (83) | .180 |
| Nonresponders | 12 (100) | |
| Prior interferon-α therapy | ||
| Responders | 19 (79) | .113 |
| Nonresponders | 12 (100) | |
| Other prior therapy | ||
| Responders | 7 (29) | .092 |
| Nonresponders | 7 (58) | |
| Initial imatinib dose 600 mg daily, no. (%)† | ||
| Responders | 10 (43) | .255 |
| Nonresponders | 3 (25) | |
| Time from diagnosis to imatinib therapy, d | ||
| Responders | 928 | .037 |
| Nonresponders | 1812 |
| Characteristic . | Value . | P . |
|---|---|---|
| Male sex, no. (%) | ||
| Responders | 15 (63) | 1.00 |
| Nonresponders | 7 (58) | |
| Median age at diagnosis, y (range) | ||
| Responders | 51 (28-76) | .048 |
| Nonresponders | 61 (24-71) | |
| Hemoglobin, g/dL | ||
| Responders | 13.1 (10.0-16.3) | .575 |
| Nonresponders | 12.5 (10.3-15.8) | |
| White cell count, ×103/L | ||
| Responders | 12.0 (2.5-70.8) | .373 |
| Nonresponders | 17.8 (4.7-116) | |
| Platelet count, ×103/L | ||
| Responders | 265.5 (19-935) | .098 |
| Nonresponders | 350 (99-1372) | |
| Peripheral blood basophil count, % | ||
| Responders | 4 (0-31) | .938 |
| Nonresponders | 6 (0-16) | |
| Peripheral blood eosinophil count, % | ||
| Responders | 1 (0-8) | .441 |
| Nonresponders | 2 (0-3) | |
| Peripheral blood blast count, % | ||
| Responders | 0 (0-11) | .657 |
| Nonresponders | 0 (0-5) | |
| Bone marrow blast count, % | ||
| Responders | 1 (0-13) | .234 |
| Nonresponders | 3 (0-18) | |
| Spleen size, cm below costal margin | ||
| Responders | 0 (0-11) | .806 |
| Nonresponders | 0 (0-10) | |
| Chronic phase with CE* | ||
| Responders | 6 (26) | .874 |
| Nonresponders | 3 (27) | |
| Deletion of derived chromosome 9, no. (%) | ||
| Responders | 2 (8) | .717 |
| Nonresponders | 1 (8) | |
| Prior hydroxyurea therapy | ||
| Responders | 20 (83) | .180 |
| Nonresponders | 12 (100) | |
| Prior interferon-α therapy | ||
| Responders | 19 (79) | .113 |
| Nonresponders | 12 (100) | |
| Other prior therapy | ||
| Responders | 7 (29) | .092 |
| Nonresponders | 7 (58) | |
| Initial imatinib dose 600 mg daily, no. (%)† | ||
| Responders | 10 (43) | .255 |
| Nonresponders | 3 (25) | |
| Time from diagnosis to imatinib therapy, d | ||
| Responders | 928 | .037 |
| Nonresponders | 1812 |
CE indicates clonal cytogenetic evolution.
Two patients (1 responder and 1 nonresponder) were subsequently found to fulfill the criteria for accelerated phase (platelet count < 100/nL unrelated to therapy, and basophils in the blood > 20%).
Patients with CE were classified as in accelerated phase in the phase 2 imatinib studies (but not in the IRIS study) and therefore treated with an initial dose of 600 mg imatinib daily.